“Sotrovimab was deliberately designed with a mutating virus in mind," said Vir Chief Executive George Scangos, adding that the drug was targeting a region of the spike protein that was highly unlikely to mutate. The antibody is designed to latch on to the spike protein on the surface of the coronavirus, but Omicron has been found to have an unusually high number of mutations on that protein. For confirmation, a pseudovirus with all of the Omicron mutations is now being tested, with an update expected by the end of the year, GSK added in its statement.
0 Comments
Leave a Reply. |